Bristol-Myers Squibb Compnay

Reginald O Cann

Jeffrey A Robl

Jun Li

James J Li

Chenkou Wei

Lawrence J Kennedy

Michael A Galella

Haixia Wang

Xinhua Qian

Edward J Delaney

Rajendra P Deshpande

Luca Parlanti

Junying Fan

Jie Jack Li

Laxma Reddy Kolla

Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds of formula I: or stereoisomers or pharmaceutically acceptable salts thereof, wherein G, Q, X, Y, R, R, and Rare defined herein.

Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors

A process is provided for the process for preparing a pyrrolotriazine aniline p38 kinase inhibitor such as amide II by the direct aminolysis of the ester I wherein ester I is reacted with a strong organometallic base, such as hexyllithium or n-butyllithium and the desired amine such as n-propylamine to form the amide II.

Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors

Growing community of inventors

Princeton Junction, NJ, United States of America

Reginald O Cann